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Introduction
Despite continuing efforts during the last decades, there is no ‘ideal
prosthetic valve substitute’. Every valve prosthesis invokes new
pathophysiological processes, including the risks of thromboembol-
ism, prosthetic endocarditis, and structural valve deterioration (SVD)
or non-structural valve deterioration with consequent need for
reintervention (Figure 1). Bioprostheses are now increasingly used in
preference to mechanical valves in the aortic position but valve dys-
function may occur over time. The literature concerning surgical
prostheses has taught us that bioprosthetic valve dysfunction is a
complex phenomenon whose understanding requires more than the
reporting of reintervention. Further research must encompass biolo-
gical, pathological and haemodynamic mechanisms, use of contem-
porary non-invasive imaging, evaluation of the true incidence while
avoiding methodological pitfalls, and identification of clinical, tech-
nical, and prosthesis-specific predictors.
Since introduction in 2002 and broader clinical use in 2007, pene-
tration of transcatheter aortic valve implantation (TAVI) has grown
exponentially as a result of accruing evidence demonstrating safety
and efficacy, and reduced invasiveness compared with surgery. TAVI
is now the recommended therapy in elderly patients with aortic sten-
osis who are inoperable or at increased surgical risk1 and recent evi-
dence has demonstrated at least its equivalence to surgery in
intermediate and high-risk cohorts.2–4 However, our knowledge con-
cerning the clinical outcomes of TAVI beyond 5 years is still limited.
Although SVD is likely to be the main mechanism of bioprosthetic
valve dysfunction in the longer term, definitions of SVD vary and
follow-up studies are scarce. While it is possible to draw lessons
from longer term experience with surgical bioprostheses, there are
fundamental differences between TAVI and surgical aortic valve re-
placement (SAVR) (i.e. remaining valve calcification, mechanical
stress, crimping of the valve tissue, valve leaflet geometry, balloon ex-
pansion or dilation, differences in haemodynamic profile, and patient-
prosthesis mismatch), which may impact on the natural history of
SVD (see Supplementary material online, Appendix). Critically, ex-
tended knowledge of the durability of TAVI is essential as we enter
the time (>5 years after implantation) when SVD starts to occur in
surgical bioprostheses. This knowledge assumes even greater import-
ance as we consider expanding the indications for TAVI to lower risk
and younger patients. As such, standardizing the definitions of valve-
and patient-oriented durability outcomes is of paramount import-
ance to enable objective evaluation of existing and novel TAVI pros-
theses, and their comparative efficacy vs. SAVR.
In this context, the European Association of Percutaneous
Cardiovascular Intervention (EAPCI) determined that improved
characterization of long-term TAVI outcomes was timely. Two face-
to-face meetings (September 2016, London; January 2017, Frankfurt)
involving members of the EAPCI, the European Society of Cardiology
(ESC), and the European Association for Cardio-Thoracic Surgery
(EACTS) representing interventional cardiology, clinical cardiology,
imaging and surgery, provided much of the discussion to inform the
present document. Herein, we present the available evidence on
TAVI SVD, addressed in terms of existing definitions, predictors, and
Figure 1 Causes of bioprosthetic valve dysfunction.
























































































detection. In parallel, we present a standardized definition of SVD
and a new patient-oriented clinical end point named bioprosthetic
valve failure (BVF) for use in future studies, which aims to capture the
clinically relevant manifestations and consequences of SVD or other
forms of bioprosthetic valve dysfunction. This effort precedes a regis-
try initiated within the ESC European Observational Registries
Programme (EORP) which will evaluate the incidence, presentation,
mode, and timing of bioprosthetic valve dysfunction in a contempor-
ary real-world setting. The ultimate goals of this multidisciplinary col-
laboration are to improve the characterization of SVD and BVF in
line with similar ongoing efforts by the Valve Academic Research
Consortium (VARC) 3 and optimize the future utilization of TAVI.
Existing definitions of structural
valve deterioration
Survival without valve reintervention or explant for SVD is an out-
come still used by some published series to assess the durability of
surgical bioprostheses.5 However, surgical guidelines for event re-
porting after cardiac valve interventions have not supported this ap-
proach since 2008, and stipulate that SVD should also be defined by
clinically detectable measures other than the need for reoperation
for a failing bioprosthesis (i.e. using echocardiographic criteria).6 In
2009, Zoghbi et al.7 published a series of recommendations for the
evaluation of prosthetic valves using echocardiography and Doppler
ultrasound. Possible stenosis was defined as peak prosthetic aortic jet
velocity 3–4 m/s, mean gradient 20–35 mmHg, and effective orifice
area 0.8–1.2 cm2. Significant stenosis was defined as peak prosthetic
aortic jet velocity >4 m/s, mean gradient >35 mmHg, and effective
orifice area <0.8 cm2. The 2012 ESC guidelines, written in collabor-
ation with the EACTS, recommend annual echocardiography beyond
the first 5 years following bioprosthetic valve implantation (and earlier
in young patients) to detect early evidence of ‘SVD, leaflet stiffening,
calcification, reduced effective orifice area, and/or regurgitation’.1
Based on these guidelines, the transprosthetic gradients should be in-
terpreted in comparison with the baseline values. This requires an
early postoperative assessment to set up a reference point for future
investigations and to detect important conditions such as patient-
prosthesis mismatch and left ventricular dysfunction. Reoperation is
recommended in symptomatic patients with a significant increase in
transprosthetic gradient or severe regurgitation (Class I, Level of
Evidence C) and should be considered in asymptomatic patients with
significant bioprosthetic valve dysfunction, provided they remain at
low-surgical risk (Class IIa, Level of Evidence C). The VARC-2 recom-
mendations also suggest echocardiography as the principal imaging
modality for assessment of bioprosthetic valve function immediately
before initial hospital discharge (to establish baseline parameters) and
at 6 months, 1 year, and annually thereafter.8 VARC-2 defines SVD as
(i) valve-related dysfunction (mean aortic gradient >_20 mmHg, effect-
ive orifice area <_0.9–1.1 cm2, and/or dimensionless valve index <0.35,
and/or moderate or severe prosthetic valve regurgitation) or (ii)
need for a repeat procedure (TAVI or SAVR). Lancellotti et al.9 sug-
gested incorporating an increase in mean gradient during stress echo-
cardiography or at follow-up (possible obstruction 10–19 mmHg;
significant obstruction >_20 mmHg). In a recent surgical series,
Bourguignon et al.10 defined SVD using strict echocardiographic
criteria independent of symptomatic status, including severe aortic
stenosis (mean transvalvular gradient >40 mmHg) and severe aortic
regurgitation (effective regurgitant orifice area >0.30 cm2, vena
contracta >0.6 cm). Of note, this definition relies on the systematic
implementation, recording and reporting of echocardiographic data
at pre-defined follow-up intervals, which make data interpretation
problematic if these conditions are not observed.10
Assessment and quantification of
bioprosthetic valve dysfunction
The clinical course of patients with bioprosthetic valves should be
monitored periodically, with the interval between routine follow-up
visits determined according to cardiac status, comorbidities, and
other clinical factors. Various imaging techniques are available for de-
tection of bioprosthetic valve dysfunction. These include 2D/3D
echocardiography, multi-detector computed tomography (MDCT)
and magnetic resonance imaging (MRI).11–13 Echocardiography is a
‘functional’ imaging modality and superior for the demonstration of
valve haemodynamics (i.e. increased transvalvular gradient, valve re-
gurgitation), whereas MDCT provides more ‘anatomical’ and struc-
tural information. MRI has the potential to combine anatomical and
functional information but is not always readily available and experi-
ence in the assessment of bioprosthetic valve dysfunction is limited.
These considerations have implications for the application of differ-
ent imaging modalities in the assessment of bioprosthetic valve
durability.
Echocardiography
Periodic echocardiographic surveillance is currently the reference
standard for detection of SVD in cases unidentified at reoperation
or autopsy. Stenosis or regurgitation of the bioprosthetic valve
should be reported using validated quantitative or semi-
quantitative methods.9 The term deterioration implies changes in-
trinsic to the valve (including wear, fracture, calcification, leaflet
tear, and/or disruption of any component). Transoesophageal
imaging can improve visualization of morphological aspects of the
valve prosthesis and the additional role of 3D echocardiography in
this setting is yet to be defined.
Multi-detector computed tomography
Multi-detector computed tomography may be more sensitive than
echocardiography in detecting valve thrombosis, particularly at early
stages of the process (i.e. subclinical leaflet thrombosis without
haemodynamic consequences).14,15 Multi-detector computed tom-
ography criteria for TAVI thrombosis include hypo-attenuated leaflet
thickening (with or without reduced leaflet motion of one or more
leaflets, identifiable in two or more multiplanar curved reconstruc-
tions).11 Specific MDCT measurements include stent frame expan-
sion and eccentricity index, number of leaflets with hypo-attenuated
leaflet thickening, as well as degree of leaflet thickening, motion re-
duction and calcification.11 Importantly, MDCT cannot determine
aortic valve gradients and is therefore of diminished utility for the
diagnosis of SVD.













































bioprosthetic valves in the
aortic position
Surgical bioprostheses
Several large series have reported the long-term outcomes of SAVR
bioprostheses with mixed results (Table 1). Importantly, the age of
patients undergoing SAVR in these studies was on average lower
than that of patients included in TAVI series, which makes cross-
study comparisons inappropriate on the ground of long-term durabil-
ity. As noted above, some of the surgical series evaluate durability in
terms of survival or survival without reintervention; others expand
the definition of SVD with criteria of haemodynamic progression.
In a large series evaluating 2405 Carpentier-Edwards bioprostheses,
survival without reintervention was 98 ± 0.2%, 96 ± 1%, and 67 ± 4%
at 5, 10, and 20 years, respectively.18 Bourguignon et al.10 evaluated
2758 Carpentier-Edwards bioprostheses using clinical and echocar-
diographic criteria, and reported SVD in 157 patients (123 of whom
required reintervention) over a cumulative follow-up of 18 404
valve-years. All cases of SVD were late events and actuarial freedom
from SVD at 15 and 20 years was 78.6 ± 2.2% and 48.5 ± 4.6%, re-
spectively. In the Johnstone et al.5 series assessing SVD in 12 569 pa-
tients (81 706 patient-years), actuarial estimates of explant for SVD
at 10 and 20 years were 1.9% and 15% overall. Porcine bioprostheses
(Hancock II) have also demonstrated long-term durability in patients
aged 60 years or older16 while an accelerated pattern of SVD was
observed with the Mitroflow prosthesis in approximately one-third
of patients.19 A study of 430 patients treated with a stentless
bioprosthesis reported freedom from reoperation in 91.0% and
75.0% at 10 and 15 years, and freedom from reoperation for SVD in
95.9% and 82.3%, respectively.17 Notably, outcomes vary with differ-
ent surgical bioprostheses as demonstrated in recent post-market
surveillance of 43 782 valves in England and Wales.20
Transcatheter bioprostheses
Transcatheter aortic valve implantation has only been widely avail-
able since 2007 and mainly used in elderly patients, in whom data
concerning long-term durability are limited (Table 2). Serial annual
echocardiography in the PARTNER A trial comparing TAVI using a
balloon-expandable prosthesis with SAVR in high-risk subjects22
demonstrated unchanged transvalvular gradient and aortic valve area
up to 5 years (although only 53 patients remained at risk at 5-year
follow-up). Published follow-up data of a pivotal trial using a self-
expanding TAVI prosthesis vs. SAVR are available up to 3 years, sug-
gesting more favourable valve haemodynamics for TAVI without dif-
ferences in SVD.24 In this trial, severe patient-prosthesis mismatch
was more common in patients treated with SAVR than those treated
with TAVI, and associated with higher 1-year mortality.25
The Canadian and Italian Registries demonstrated stable valve
gradients over 5 years and very low rates of SVD of 3.4% and
4.2%, respectively.21,23 However, it should be noted that few pa-
tients were still alive at 5 years (reflecting their advanced age and
significant comorbidities at the time of valve implantation) and
that definitions of SVD were not comparable. Only two unpub-
lished single-centre series currently provide data on ‘long-term’
durability (>5 years) in patients treated before 2011 (Eltchaninoff
et al.26 Webb et al.27 both presented at Transcatheter Valve
....................................................................................................................................................................................................................
Table 1 Long-term durability after surgical aortic valve replacement
Author Year N Prosthesis Results
David et al.16 2010 1134 Hancock II • Survival: 19 ± 2% and 7 ± 3% at 20 and 25 years, respectively
• Freedom from SVDa: 63 ± 4% at 20 years
• Freedom from reoperation: 65 ± 4% at 20 years
Mohammadi
et al.17
2012 430 Freestyle • Survival: 60.7% and 35.0% at 10 and 15 years, respectively
• Freedom from reoperation: 91.0% and 75.0% at 10 and 15 years, respectively
• Freedom from reoperation for SVDb: 95.9% and 82.3% at 10 and 15 years, respectively
Forcillo et al.18 2013 2405 Carpentier-Edwards • Survival: 78 ± 2%, 55 ± 2%, 34 ± 2%, and 16 ± 2% at 5, 10, 15, and 20 years, respectively
• Freedom from reoperation: 98 ± 0.2%, 96 ± 1%, and 67 ± 4% at 5, 10, and
20 years, respectively
Senage et al.19 2014 617 Mitroflow • Survival: 70% at 20 years
• Freedom from SVDc: 92% at 5 years
Bourguignon
et al.10
2015 2758 Carpentier-Edwards • Survival: 14 ± 2% at 20 years
• Valve-related survival: 64 ± 4% at 20 years
• Freedom from SVDd: 79 ± 2% and 49 ± 5% at 15 and 20 years, respectively
• Freedom from explant due to SVDd: 84 ± 2% and 54 ± 5% at 15 and 20 years, respectively
Johnstone
et al.5
2015 12 569 Carpentier-Edwards • Incidence of explant due to SVDa: 2% and 15% at 10 and 20 years, respectively
SVD, structural valve deterioration.
aUndefined.
bDefined as any change in function resulting from any valve abnormality excluding infection or thrombosis.
cDefined as progression of aortic transprosthetic gradient >_30 mmHg associated with a decreased effective orifice area <_1 cm2 or intra-prosthetic aortic regurgitation >2/4.
dDefined as severe aortic stenosis (mean transvalvular gradient >40 mmHg) or severe aortic regurgitation (effective regurgitant orifice area >0.30 cm2, vena contracta >0.6 cm).

































































..Therapeutics, Chicago, 2016). In the Rouen series (n = 242), SVD
was defined as mean transvalvular gradient >_20 mmHg plus an in-
crease >10 mmHg over time and/or >_moderate aortic regurgita-
tion that was not present 30 days following valve implantation.
Using this definition, only 1 patient had ‘definite’ SVD (redo TAVI
for elevated gradient) and 3 asymptomatic patients had ‘possible’
SVD (mean gradient >20 mmHg and increase >10 mmHg in com-
parison with 30-day echocardiography). No patients had a gradi-
ent >40 mmHg. In the Vancouver series (n = 266), freedom from
SVD defined as need for reintervention was 97.6% while freedom
from SVD defined as severe stenosis, regurgitation or need for
reintervention was 84.6% (both at 8-year follow-up). Overall,
three patients were alive >10 years after TAVI with no signs of
SVD (one in France, two in Canada).
Suggested definitions of structural
valve deterioration and
bioprosthetic valve failure
In building standardized definitions for the purpose of future studies,
the Task Force reached consensus on the following points:
(1) There should be clear distinction between SVD (the principal aeti-
ology) and BVF (the clinical correlate).
(2) Structural valve deterioration causes irreversible dysfunction
whereas other pathological causes of bioprosthetic valve dysfunc-
tion (i.e. thrombosis, endocarditis) are potentially reversible and
should be identified and categorized separately. However, the
thrombotic or endocarditic process qualifies as a cause of BVF if it
leads to lasting or permanent bioprosthetic valve dysfunction.
(3) Non-structural valve dysfunction (i.e. intra-prosthetic or paravalvu-
lar regurgitation, prosthesis malposition, patient-prosthesis mis-
match, late embolization) may occur early after TAVI as a result of
technical issues. Non-structural valve dysfunction resulting in valve-
related death, reintervention, and haemodynamic dysfunction [i.e.
severe new or worsening (>2þ/4þ) paravalvular aortic regurgita-
tion] qualifies as a cause of BVF.
(4) Echocardiography is the principal imaging modality for the detection
of SVD and the best and most accessible way to detect serial
changes in valve function. Transprosthetic gradients should be
determined in at least two consecutive measurements to account
for detection bias and minimize inconsistencies related to the differ-
ent types of bioprosthesis implanted. After TAVI and SAVR,
echocardiography should be performed before discharge or
within 30 days after valve implantation (i.e. baseline imaging), at
1 year after valve implantation and annually thereafter (with add-
itional follow-up assessments and/or integration of other imaging
modalities as necessary and/or determined by the attending phys-
ician) (Figure 2).
Structural valve deterioration
Structural valve deterioration includes permanent intrinsic changes
of the valve (i.e. leaflet tear, calcification, pannus deposition, flail, or fi-
brotic leaflet) leading to degeneration and/or dysfunction, which in
turn may result in stenosis or intra-prosthetic regurgitation (Table 3).
Structural valve deterioration can be detected using imaging studies
or at the time of reoperation or autopsy, and can arise in both symp-
tomatic and asymptomatic patients. Structural valve deterioration
can be characterized as ‘haemodynamic dysfunction’ and/or ‘mor-
phological SVD’.
Haemodynamic structural valve deterioration
The diagnosis is based on permanent haemodynamic changes in valve
function assessed by means of echocardiography, even without evi-
dence of morphological SVD (‘isolated haemodynamic dysfunction’).
Morphological SVD may be diagnosed in patients with haemo-
dynamic SVD by echocardiography or other imaging modalities. For
simplicity, the Task Force specifies two degrees of haemodynamic
SVD (moderate and severe—the detection of mild haemodynamic
dysfunction being of less clinical importance). Moderate SVD is
defined as (i) mean gradient >_20 and <40 mmHg and/or >_10 and
<20 mmHg change from baseline (before discharge or within 30 days
of valve implantation) and/or (ii) moderate new or worsening (>1þ/
4þ) intra-prosthetic aortic regurgitation. Severe haemodynamic SVD
is defined as (i) mean gradient >_40 mmHg and/or >_20 mmHg change
from baseline (before discharge or within 30 days of valve implant-
ation) and/or (ii) severe new or worsening (>2þ/4þ) intra-
prosthetic aortic regurgitation.
Morphological structural valve deterioration
The diagnosis is based on imaging findings, regardless of whether
reintervention is performed. In case of autopsy, the diagnosis of mor-
phological SVD should be reassessed and confirmed or rejected
based on the pathological findings. Morphological SVD encompasses
abnormalities of the following domains: leaflet integrity (i.e. torn or
flail causing intra-frame regurgitation), leaflet structure (i.e.
....................................................................................................................................................................................................................
Table 2 Long-term durability after transcatheter aortic valve implantation
Author Year N Prosthesis Results
Toggweiler et al.21 2013 88 Cribier-Edwards or Edwards Sapien • Survival: 35% at 5 years
Mack et al.22 2015 348 Edwards Sapien • Mortality: 68% at 5 years
• Reintervention due to SVDa: 0% at 5 years
Barbanti et al.23 2015 353 Medtronic CoreValve • Mortality: 55% at 5 years
• Bioprosthetic valve dysfunction: 1.4%
at 5 years
SVD, structural valve deterioration.
aUndefined.















































pathological thickening and/or calcification causing valvular stenosis
or central regurgitation), leaflet function (i.e. impaired mobility result-
ing in stenosis and/or central regurgitation), and strut/frame (i.e. frac-
ture or failure).
Bioprosthetic valve failure
The term BVF integrates severe SVD (i.e. the aetiology) with its clin-
ical consequences (thereby avoiding over-interpretation of valve-
related outcomes in asymptomatic patients with no clinical impact)
and is recommended by the Task Force as the main outcome of
interest in studies assessing the long-term performance of TAVI and
SAVR (Figure 3, Table 4). Importantly, BVF may occur in the setting of
SVD but also as the consequence of pathophysiological processes un-
related to SVD, such as thrombosis, endocarditis or non-structural
valve dysfunction. BVF includes any of the following: (i) bioprosthetic
valve dysfunction at autopsy, very likely related to the cause of death,
or ‘valve-related death’, defined as any death caused by bioprosthetic
valve dysfunction in the absence of confirmatory autopsy; (ii) aortic
valve reintervention (i.e. valve-in-valve TAVI, paravalvular leak
closure or SAVR); and (iii) severe haemodynamic SVD. Based on
the degree of certainty, BVF can be categorized as definite (i.e. aut-
opsy, reintervention, severe haemodynamic SVD) or probable
(i.e. valve-related death), and early (i.e. up to 30 days) or late (i.e. >30
days) according to the timing of onset after valve implantation.
Survival analysis for bioprosthetic
valve failure: key considerations
Assessing the durability of biological prostheses poses important
challenges and a number of preliminary questions. First, should BVF
be considered a longitudinal or time-dependent outcome measure?
Second, what is the inherent bias of estimating BVF in an elderly
population? Third, is there a statistical approach to best address these
Figure 2 Suggested management algorithm at echocardiographic follow-up. HD, haemodynamic dysfunction; MDCT, multi-detector computed
tomography; SVD, structural valve deterioration; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; VHD, valvular
heart disease.
Table 3 Structural valve deterioration
Moderate haemodynamic SVD (any of the following)
Mean transprosthetic gradient >_20 mmHg and <40 mmHg
Mean transprosthetic gradient >_10 and <20 mmHg change from
baseline
Moderate intra-prosthetic aortic regurgitation, new or worsening
(>1þ/4þ) from baseline
Severe haemodynamic SVD (any of the following)
Mean transprosthetic gradient >_40 mmHg
Mean transprosthetic gradient >_20 mmHg change from baseline
Severe intra-prosthetic aortic regurgitation, new or worsening
(>2þ/4þ) from baseline
Morphological SVD (any of the following)
Leaflet integrity abnormality (i.e. torn or flail causing intra-frame
regurgitation)
Leaflet structure abnormality (i.e. pathological thickening and/or
calcification causing valvular stenosis or central regurgitation)
Leaflet function abnormality (i.e. impaired mobility resulting in
stenosis and/or central regurgitation)
Strut/frame abnormality (i.e. fracture)
Haemodynamic and morphological SVD
SVD, structural valve deterioration.
























































































challenges? The following paragraphs will discuss these points and
focus on best practice in survival analysis for BVF.
Longitudinal vs. time-dependent
outcomes
An important preliminary distinction is between valve and patient
outcomes. Valve outcomes pertain to the intrinsic durability of the
bioprosthesis (i.e. they address the question ‘what is the probability
of this valve lasting over time without failure?’). In contrast, patients
are more interested in their individual probability of experiencing a
valve failure-related event during their remaining lifetime (i.e. ‘what is
the probability of my valve failing before I die?’). Importantly, some
valve outcomes (including haemodynamic SVD) are typically longitu-
dinal in nature, which means that they evolve with time and do not
occur at a precise instant. To capture valve outcomes while minimiz-
ing bias, it is important to consider the timing of observations, or
‘snapshots’. For example, when assessing the presence or absence of
haemodynamic SVD by measurement of mean gradient using
Doppler echocardiography, there is an important difference if the
snapshots are infrequent while the observed condition changes rap-
idly (which introduces data aliasing). On the other hand, there is a
risk of overestimating adverse valve outcomes if the snapshots are
opportunistic (i.e. if echocardiography is performed at any time in
symptomatic patients). These issues are obviously magnified when
snapshots are heterogeneously derived across different patient co-
horts. At variance with valve outcomes, patient outcomes are more
typically time dependent in that they reflect the occurrence of an
event from the time of implantation to a precise landmark (i.e. death
or reintervention).
Competing risk and informative
censoring
Death exerts a competing risk against the risk of a valve to fail over
time. In fact, if the patient dies at a time when the valve is functioning
normally, then there is no way to predict how long the valve would
have lasted if the patient had survived. In other words, if BVF occurs
at some time during follow-up, then the end point is easily captured.
In contrast, if the patient dies with no bioprosthetic valve dysfunction,
we cannot be sure about the true durability of the prosthesis because
death obscures the chance for that valve to become dysfunctional at
a later time point. This bias is obviously more likely to occur in an old
and frail population (where the mortality rate is higher per se). The
term ‘censoring’ refers to the situation when the information regard-
ing an end point for a given patient is only partially known. For ex-
ample, a patient may be censored in a study of TAVI durability
because (i) BVF does not occur during the follow-up period; (ii) the
patient dies before the end of the follow-up period (i.e. competing
risk); or (iii) the patient is lost to follow-up. A typical assumption of
outcome studies is that censoring can be ignored or is non-
informative. Based on such an assumption, the survival experience of
a patient who dies or is lost to follow-up may be completed by statis-
tical means (i.e. Kaplan–Meier analysis) and the outcome of interest
estimated as part of a virtual ‘death-free environment’ where all pa-
tients reach final follow-up assessment. However, the typical assump-
tion of non-informative censoring is false in TAVI durability studies.
Indeed, there is a clear dependence between the competing risk of
death and BVF (i.e. informative censoring) in that (i) patients who die
before BVF are generally older than those who do not and (ii) the
rate of BVF is lower in older patients.
Actuarial vs. actual analysis
The relevant question for a TAVI patient does not necessarily pertain
to the intrinsic durability of the valve, but to the probability of a clin-
ical event related to bioprosthetic valve dysfunction during the
course of the remaining life. In this regard, conventional Kaplan–
Meier analysis (a type of actuarial analysis) may lead to incorrect
Figure 3 Suggested assessment of bioprosthetic valve failure
(BVF) in outcome studies of transcatheter aortic valve implantation
(TAVI) or surgical aortic valve replacement (SAVR). SVD, structural
valve deterioration.
Table 4 Bioprosthetic valve failure
Autopsy findings of bioprosthetic valve dysfunction, likely related to
the cause of death, or valve-related death (i.e. any death caused by
bioprosthetic valve dysfunction or sudden unexplained death fol-
lowing diagnosis of bioprosthetic valve dysfunction)
Repeat intervention (i.e. valve-in-valve TAVI, paravalvular leak closure or
SAVR) following confirmed diagnosis of bioprosthetic valve dysfunction
Severe haemodynamic SVD
SAVR, surgical aortic valve replacement; SVD, structural valve deterioration;
TAVI, transcatheter aortic valve implantation.
























































































estimates, since each event causes an increasingly significant drop of
the curve for survival free from BVF (as long as censoring occurs
over the duration of follow-up) (Figure 4). Kaplan–Meier estimates
may be useful for those interested in the hypothetical durability of a
valve ‘assuming patients’ immortality’, particularly if statistical correc-
tion for informative censoring is applied. Indeed, the statistical
method of inverse probability weighting may correct for the bias of
informative censoring and provide a better estimate of true valve per-
formance. Importantly, specific rules for the correct reporting of
Kaplan–Meier curves should be respected: (i) indicating the number
of patients at risk at each time point below the x-axis; (ii) reporting
95% confidence intervals; and (iii) cutting the event-free survival
curve when less than 10% of the initial patient cohort is available. In
contrast to the actuarial method, the actual method is the correct
probability that should be used for clinical predictions, patient man-
agement decisions and cost-effectiveness studies. This method, based
on a cumulative incidence function, provides lower estimates than ac-
tuarial Kaplan–Meier analysis and might have greater clinical utility in
the context of TAVI durability studies.
Areas of future research and
implications for study design
The dawn of a new era in the treatment of valve disease using trans-
catheter techniques is ongoing. The clinical successes of TAVI are
increasingly well described by both randomized trials and observa-
tional research. However, in the process of moving to less invasive
treatment of younger and lower risk patients, it is important to better
appraise the long-term durability characteristics of current and future
TAVI prostheses. To better achieve this goal, we have proposed
practical and standardized definitions of SVD and BVF and provide
recommendations for the timing and modalities of clinical and imaging
follow-up assessment. For the sake of comparability, these should
also be extended to the evaluation of current and future surgical bio-
prostheses, whose long-term efficacy and durability are currently ad-
dressed by a surprisingly small body of literature.
Important information concerning bioprosthetic valve dysfunction
and BVF, and their relationship with individual patient characteristics,
bioprosthetic valve design and techniques for valve implantation will
provide valuable data to guide new developments in technology and
implantation techniques. Accepted and carefully defined imaging
characteristics will allow identification of bioprosthetic valve dysfunc-
tion due to mechanical factors, endocarditis and thrombotic phe-
nomena. While the degenerative process seems comparable in
frequency and anatomical/pathological characteristics to that
observed with surgical bioprostheses,28,29 recent evidence of valve
leaflet thickening and thrombosis requires further investigation since
(i) it remains unclear whether these phenomena are of clinical rele-
vance and somehow linked to SVD12 and (ii) the optimal antithrom-
botic regimen for this condition is yet to be determined.
Within the EORP programme, EAPCI aims to coordinate a large
European registry of TAVI patients treated >5 years ago by engaging
the pioneering European centres who started TAVI programmes at
the early inception of this treatment strategy. The registry will focus
on two main aspects of data collection: (i) prevalence of BVF at latest
follow-up and (ii) progression of SVD in patients treated at different
time intervals. Some important remaining gaps in knowledge that
need to be recognized include the minimal follow-up data beyond
10 years and our inability to address the significant changes in device
characteristics and procedural techniques over time.30
Notwithstanding these limitations, the results of the EAPCI/EORP
registry will be instrumental in achieving a better understanding of
current results and the opportunities for TAVI in younger patients.
Moreover, they will provide a benchmark for comparing the results
of TAVI with those of surgically implanted valves.
Supplementary material
Supplementary material is available at European Heart Journal online.
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